» Articles » PMID: 27461039

The Acute Lethal Dose 50 (LD50) of Caffeine in Albino Rats

Overview
Publisher Elsevier
Specialties Pharmacology
Toxicology
Date 2016 Jul 28
PMID 27461039
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

An acute LD50 is a statistically derived amount of a substance that can be expected to cause death in 50% of the animals when given by a specified route as a single dose and the animals observed for a specified time period. Although conducting routine acute toxicity testing in rodents has been criticized, it can serve useful functions and also have practical implications. Material safety data sheets (MSDS) will reflect the acute toxicity of a substance and may require workers to wear protective gear, if appropriate, based on the LD50. There is no information in the scientific published literature which calculates a mean LD50 and standard deviation for caffeine administered orally to rats, using studies performed under good laboratory practice (GLP) or equivalent. This report does that and should be useful to manufacturers, packagers, transporters and regulators of this material. Using data from studies that are reproducible and reliable, the most accurate estimate of the acute LD50 of caffeine administered orally in male albino rats is hereby reported to be 367/mg/kg.

Citing Articles

Kilogram scale facile synthesis and systematic characterization of a Gd-macrochelate as T-weighted magnetic resonance imaging contrast agent.

Shi M, Xiong W, Feng J, Wu L, Yang J, Lu Y J Nanobiotechnology. 2024; 22(1):162.

PMID: 38594700 PMC: 11005285. DOI: 10.1186/s12951-024-02394-8.


Common questions and misconceptions about caffeine supplementation: what does the scientific evidence really show?.

Antonio J, Newmire D, Stout J, Antonio B, Gibbons M, Lowery L J Int Soc Sports Nutr. 2024; 21(1):2323919.

PMID: 38466174 PMC: 10930107. DOI: 10.1080/15502783.2024.2323919.


In Silico Analyses of a Promising Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis Targeting Superoxide Dismutase I Protein.

Pereira G, Abrahim-Vieira B, De Mesquita J Pharmaceutics. 2023; 15(4).

PMID: 37111580 PMC: 10143751. DOI: 10.3390/pharmaceutics15041095.


Paraxanthine safety and comparison to caffeine.

Szlapinski S, Charrette A, Guthrie N, Hilmas C Front Toxicol. 2023; 5:1117729.

PMID: 36818692 PMC: 9932512. DOI: 10.3389/ftox.2023.1117729.


Characterisation of cytotoxicity and immunomodulatory effects of glycolipid biosurfactants on human keratinocytes.

Adu S, Twigg M, Naughton P, Marchant R, Banat I Appl Microbiol Biotechnol. 2022; 107(1):137-152.

PMID: 36441210 PMC: 9750927. DOI: 10.1007/s00253-022-12302-5.